Anti-inflammatory Binding Molecules Targeting Citrullinated Epitopes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases, particularly those involving the synovium and citrulline-related conditions, lack effective compounds to inhibit pathogenesis and prevent joint damage, with existing therapies often requiring aggressive and long-term drug regimens.
Innovation Solution
Development of specific binding molecules reactive with citrullinated epitopes on p15 and/or p17 for use in pharmaceutical compositions to treat or prevent inflammatory diseases, including rheumatoid arthritis, by administering a therapeutically effective amount of these molecules to patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If specific binding molecules reactive with citrullinated epitopes are administered, then inflammation is reduced and joint damage is prevented, but the complexity of the pharmaceutical composition increases
Solution Approach 1:
The patent uses specific binding molecules (antibodies) as intermediaries that selectively bind to citrullinated epitopes on inflammatory proteins such as p15 and p17. These antibodies act as mediators that block the pathogenic effects of citrullinated proteins without requiring complex multi-component formulations, thereby preventing joint damage while maintaining formulation simplicity
Solution Approach 2:
The invention focuses on targeting specific molecular parameters (citrullinated epitopes) rather than broad inflammatory pathways. By identifying and binding to specific citrullinated proteins like p15 and p17, the therapy achieves high specificity and effectiveness with a relatively simple pharmaceutical composition consisting of defined antibody molecules
2Duration of action of stationary object
If aggressive and long-term drug regimens are used to treat inflammatory diseases, then disease progression is controlled, but patient quality of life deteriorates and treatment side effects increase
Solution Approach 1:
The binding molecules are designed to intervene early in the inflammatory pathway by specifically blocking citrullinated epitopes before they can trigger extensive inflammatory cascades. This preliminary action at a specific molecular target allows for more effective disease control with potentially lower and shorter-duration dosing compared to conventional broad-spectrum anti-inflammatory therapies
Solution Approach 2:
The antibodies serve as selective intermediaries that block specific citrullinated proteins involved in joint destruction without broadly suppressing the immune system. This targeted mediation approach controls disease progression while minimizing the systemic side effects associated with conventional long-term immunosuppressive regimens
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The binding molecules effectively reduce inflammation, stabilize existing inflammation, and prevent joint damage, as demonstrated in collagen antibody-induced arthritis models, with some molecules showing significant anti-inflammatory effects and ability to prevent clinical symptoms and joint erosion.
Implementation Method 1
specific binding molecules reactive with a citrullinated epitope on p15 and/or p17
Data Source
AI summary
This invention is in the field of treating or preventing inflammation in humans and animals and relates to pharmaceutical compositions and methods for treating or preventing various inflammatory conditions. In particular, the invention relates to compositions and methods for treating or preventing inflammatory conditions such as citrulline-related inflammatory diseases. The invention provides specific binding molecules directed against citrulline-containing epitopes for use in the therapy and prevention of inflammatory conditions.